Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

卷:1772

Article

Ranney, Melissa K. ; Ahmed, Ikhlas S. A. ; Potts, Kelly R. ; Craven, Rolf J.

关键词: clusterin;    doxorubicin;    breast cancer;    apoptosis;    caspase;    PARP;    histone deacetylase;    calpain;    proteasome;   

DOI  :  10.1016/j.bbadis.2007.06.004

来源: Elsevier

【 摘 要 】

Cancer chemotherapy inhibits turner growth, in part, by triggering apoptosis, and anti-apoptotic proteins reduce the effectiveness of chemotherapy. Clusterin, a chaperone-like protein that binds to apoptotic and DNA repair proteins, is induced by chemotherapy and promotes tumor cell survival. Historic deacetylase inhibitors (HDIs) such as sodium butyrate and suberoylanilide hydroxamic acid (SAHA) are pharmacological agents that induce differentiation and apoptosis in cancer cells by altering chromatin structure, and we have found that combinations of chemotherapeutic drugs such as doxorubicin and HDIs efficiently induce apoptosis, even though they paradoxically induce high levels of clusterin. The hyper-expressed form of clusterin localizes to mitochondria, inhibits cytochrome c release, and is inhibited by the proteasome. When HDIs are used as single agents, clusterin suppresses cytochrome c release and apoptosis. However, doxorubicin/HDI-induced apoptosis is not inhibited by clusterin, and clusterin-resistant apoptosis corresponds with markers of the extrinsic/receptor-mediated apoptotic pathway. Thus, chemotherapy-HDI combinations are capable of overcoming an innate anti-apoptotic pathway of minor cells, suggesting that chemotherapy-H D I combinations have potential for treating advanced stage breast cancer. (c) 2007 Elsevier B.V. All rights reserved.

【 授权许可】

Free